Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company aiming to advance treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition. The company was established in 2020 to accelerate clinical development of EoE therapies and build on the work initiated by Adare Pharmaceuticals, particularly APT-1011, which is currently in a Phase 3 clinical trial. Despite growing awareness of EoE and its underserved patient population, no first-line FDA approved treatment exists for the disease today. Ellodi Pharmaceuticals has assembled a seasoned team with deep expertise in developing and commercializing innovative therapies for gastrointestinal disorders and rare diseases. With patients and caregivers at the center of every decision we make, we are focused on developing and delivering innovative therapies that can meaningfully improve and transform the lives of patients with EoE.